AKERO THERAPEUTICS INC. - COMMON STOCK

Akero Therapeutics Announces First Patient Randomized for Dosing in Phase 2b Study of Efruxifermin (EFX) in F2/F3 NASH Patients (HARMONY)

23 3 2021 08:00:01 提供 Nasdaq GlobeNewswire

Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C

22 3 2021 16:01:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients

22 3 2021 06:30:00 提供 Nasdaq GlobeNewswire

Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

16 3 2021 08:00:03 提供 Nasdaq GlobeNewswire